QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module XVI Risk Minimisation Effectiveness Evaluation

Test your understanding of the concepts covered by GVP Module XVI: Risk Minimisation Effectiveness Evaluation.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best distinguishes implementation from effectiveness of a risk-minimisation measure?

Implementation confirms that the measure was delivered or made available, whereas effectiveness assesses whether it achieved the intended risk-reduction objective. Implementation demonstrates a clinical benefit, whereas effectiveness confirms that materials were distributed. Implementation and effectiveness are equivalent when the target population is large enough. Implementation concerns only regulatory approval, whereas effectiveness concerns only commercial performance.

Question 2 of 10 A programme improves knowledge scores but does not change the targeted prescribing behaviour. Which conclusion is most appropriate?

The knowledge objective may have been achieved, but the behavioural mechanism has not been demonstrated and workflow or feasibility barriers should be investigated. The programme is fully effective because knowledge always establishes behaviour change. The programme definitively failed at implementation. The clinical risk has necessarily increased.

Question 3 of 10 An evaluation finds low reach, but the intervention mechanism is otherwise scientifically sound. What is the most appropriate initial risk-management response?

Investigate and improve implementation, then assess whether corrective action improves reach or exposure. Immediately conclude that the intervention concept is ineffective. Replace the clinical endpoint with a measure of material quality. Discontinue the measure because low reach proves the risk no longer exists.

Question 4 of 10 Educational materials were sent to 98% of eligible prescribers, but only 35% opened or accessed them. What is the most appropriate interpretation?

The programme had high delivery reach but substantially lower actual exposure to the intervention. The programme was effective because delivery reach exceeded 95%. The programme failed clinically because access data are never relevant. The programme had high behavioural effectiveness because opening the material proves correct prescribing.

Question 5 of 10 Which approach is most appropriate when objective prescribing data are available but clinicians also provide self-reported adherence information?

Use the objective data to assess recorded behaviour while interpreting self-report as complementary evidence subject to recall and social-desirability bias. Use self-report exclusively because it reflects clinician intent. Treat both sources as interchangeable without assessing their limitations. Discard both sources unless a clinical outcome has already improved.

Question 6 of 10 What is the principal value of baseline measurement in an effectiveness evaluation?

It provides a reference for determining whether subsequent implementation, behaviour or outcomes changed meaningfully. It guarantees that any post-intervention improvement was caused by the intervention. It eliminates the need to define the target population. It replaces the need to assess data quality and confounding.

Question 7 of 10 A survey shows that prescribers can recall the name of a safety programme, but many cannot identify the required action for an at-risk patient. What does this most directly demonstrate?

Recognition or awareness without adequate evidence of the knowledge required for safe use. Successful behavioural change because programme recognition is a behavioural endpoint. Clinical effectiveness because awareness is equivalent to prevention of harm. Failure of implementation because the programme was not distributed.

Question 8 of 10 Why should qualitative interviews or observations sometimes be included in an effectiveness evaluation?

They can reveal workflow barriers, misunderstandings and contextual explanations that quantitative measures may not identify. They eliminate the need for behavioural or clinical outcome data. They provide statistically unbiased estimates of event incidence. They are required whenever distribution reach is high.

Question 9 of 10 Which statement best reflects the MAH's responsibility when affiliates or external vendors conduct effectiveness analyses?

The MAH retains ownership of the effectiveness process and must understand the methods, data quality, conclusions and resulting decisions. Delegating the analysis transfers the MAH's overall responsibility to the vendor. The MAH need only retain the final numerical result. Affiliate findings can be compared directly across countries without considering healthcare-system differences.

Question 10 of 10 What is the appropriate role of the QPPV in relation to significant risk-minimisation effectiveness findings?

To ensure significant conclusions are visible within the pharmacovigilance system, appropriately escalated and acted upon, without necessarily conducting the statistical analysis personally. To personally perform every analysis and prevent delegation to specialists. To approve effectiveness claims without reviewing limitations or proposed actions. To transfer overall responsibility to an external statistical vendor.

Knowledge Assessment: GVP Module XVI Risk Minimisation Effectiveness Evaluation

Cookie Settings